Mahmoud Mahmoudian, PhD, FRSC
Business Development, Strategic Alliances
Dr Mahmoudian’s career spans some 20 years in the Biotechnology, Pharmaceutical, and Chemical sectors. He joined Merck & Co. USA in 2007 with responsibility for strategic sourcing and partnerships in Vaccines & Biologics on a global basis. In 2005 he joined Rohm & Haas Biotech USA, as the Global Director of R&D, Alliances & Partnerships in Biotechnology (US $500m sales), directing activities in
|
|
research centres globally (USA, Europe, China, Japan), covering a diverse portfolio including healthcare, biopharmaceuticals, and biosciences. From 2002 to 2005 he was employed at Eastman Biotech USA, as the Head of Biotechnology & Strategic Alliances worldwide, responsible for R&D, alliances, and managing the growth and development of its BioProducts portfolio. From 1989 to 2002, he worked at GlaxoSmithKline England, in a variety of research, technology and management roles of increasing responsibility, managing cross functional teams in Biotechnology that led to the discovery, development, and market launch of six blockbusters with annual sales in excess of $15 billion.
Dr Mahmoudian earned his M.Sc. and Ph.D. in Biotechnology from Imperial College at the University of London, England, and was awarded a B.Sc. in Biochemistry and Human Physiology from the University of Newcastle, England. He currently serves on the International Editorial Advisory Board of seven scientific journals, is an elected Fellow of the Royal Society of Chemistry (FRSC) and has numerous publications and patents to his name.
Dr Mahmoudian's key accomplishments include 1) establishment of two biosciences business ventures, at Eastman and Rohm & Haas (2002 – 2007), via partnerships, licensing deals, and joint ventures, 2) discovery and development of six blockbusters at GlaxoSmithKline, and 3) advisor to life sciences venture funds in Philadelphia and Boston USA, consulting on business plans and market & technology assessments, resulting in investment opportunities in several early to mid-stage biotech companies.
|
